4D Molecular Therapeutics (NASDAQ:FDMT) Shares Down 8.4% – Should You Sell?

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)’s share price traded down 8.4% on Thursday . The stock traded as low as $13.96 and last traded at $13.7460. 626,080 shares traded hands during trading, a decline of 25% from the average daily volume of 833,405 shares. The stock had previously closed at $15.00.

Analyst Upgrades and Downgrades

A number of research firms recently commented on FDMT. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Friday, July 17th. B. Riley Financial restated a “buy” rating on shares of 4D Molecular Therapeutics in a research note on Monday, August 17th. Chardan Capital raised shares of 4D Molecular Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 28th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $32.00 target price on shares of 4D Molecular Therapeutics in a report on Thursday, August 13th. Finally, HC Wainwright reiterated a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Monday, July 20th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $28.56.

4D Molecular Therapeutics Price Performance

The company’s fifty day moving average price is $13.02 and its 200 day moving average price is $11.00. The company has a market capitalization of $776.56 million, a P/E ratio of -5.36 and a beta of 2.74. The company has a quick ratio of 8.03, a current ratio of 8.03 and a debt-to-equity ratio of 0.05.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. The company had revenue of $3.78 million during the quarter, compared to the consensus estimate of $3.62 million. As a group, sell-side analysts forecast that 4D Molecular Therapeutics, Inc. will post -4.07 EPS for the current year.

Insider Buying and Selling

In related news, insider David Kirn sold 58,333 shares of the company’s stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $13.90, for a total transaction of $810,828.70. Following the completion of the sale, the insider owned 767,486 shares of the company’s stock, valued at $10,668,055.40. This represents a 7.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders sold a total of 134,570 shares of company stock valued at $1,743,197 over the last three months. 7.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Sei Investments Co. lifted its holdings in 4D Molecular Therapeutics by 8.9% during the 1st quarter. Sei Investments Co. now owns 12,862 shares of the company’s stock worth $120,000 after buying an additional 1,050 shares during the period. Headlands Technologies LLC lifted its stake in shares of 4D Molecular Therapeutics by 20.6% in the second quarter. Headlands Technologies LLC now owns 19,238 shares of the company’s stock worth $256,000 after acquiring an additional 3,282 shares during the period. Impact Partnership Wealth LLC increased its position in 4D Molecular Therapeutics by 36.5% during the 4th quarter. Impact Partnership Wealth LLC now owns 15,123 shares of the company’s stock valued at $113,000 after purchasing an additional 4,045 shares during the period. Legal & General Group Plc bought a new position in 4D Molecular Therapeutics during the 2nd quarter worth approximately $59,000. Finally, Susquehanna Fundamental Investments LLC bought a new stake in shares of 4D Molecular Therapeutics in the 2nd quarter valued at $148,000. 99.27% of the stock is owned by institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc is a clinical-stage biotechnology company developing genetic medicines for serious diseases with significant unmet medical needs. The company uses its Therapeutic Vector Evolution platform to engineer and select adeno-associated virus (AAV) vectors designed to deliver genetic payloads to specific tissues and support the development of potentially durable, one-time treatments.

Its research and development programs have focused primarily on ophthalmic and pulmonary diseases.